Concepedia

R. Hehlmann

RH

Statistics

Publications

7

Citations

148

H-Index

7

Active since

1993

Affiliations

Heidelberg University(Current)

Istituti di Ricovero e Cura a Carattere Scientifico

Medizinische Fakultät Mannheim

University Medical Centre Mannheim

Uppsala University Hospital

R. Hehlmann is an author at Heidelberg University specializing in medicine, hematology, and chronic myeloid leukemia therapy.

Publications per year

1993–2016

7

Publications

7

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations

Monia Marchetti, Giovanni Barosi, Francisco Cervantes et al. · Leukemia · 2016 · 44 citations · Full text

, , +11

MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure

Mridul Agrawal, Benjamin Hanfstein, Philipp Erben et al. · Leukemia · 2014 · 22 citations

, , +4

Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy

Sebastian Kreil, Martin Müller, Tanja Lahaye et al. · ePrints Soton (University of Southampton) · 2001 · 18 citations

, , +14

Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group.

R. Hehlmann, H. Heimpel, Hossfeld Dk et al. · PubMed · 1996 · 17 citations

, , +11

Cefotaxime desensitization

G. Papakonstantinou, Johannes R. Bogner, F. Hofmeister et al. · Journal of Molecular Medicine · 1993 · 17 citations · Full text

1–5 of 7